New Brunswick, New Jersey – Johnson & Johnson stock plummeted on Wednesday as the health care giant issued lower-than-expected sales guidance for 2025, citing challenges from fluctuating foreign exchange rates. The company forecasts sales between $89.2 billion and $90 billion for the year, falling short of analysts’ expectations of $91.04 billion.

Despite this setback, Edward Jones analyst John Boylan remains optimistic about J&J’s outlook, describing the company’s guidance as achievable, if not conservative. Boylan highlights the potential impact of foreign currency fluctuations and expresses confidence in Johnson & Johnson’s new products and pipeline, particularly in cancer drugs, robotics, and other cardiovascular products.

The stock closed down 1.9% at $145.27, well below its 50-day moving average, signaling investor concern over the company’s performance in the coming months. Fourth-quarter results showed J&J reporting $2.04 earnings per share and $22.52 billion in sales, slightly surpassing analysts’ expectations.

Analysts noted strong performance in J&J’s innovative medicines portfolio, with particular success in depression drug Spravato, which saw a 44% increase in sales year over year. However, concerns loom over the impending patent expiration of Stelara, J&J’s significant immunology drug.

While medical device sales fell short of expectations at $8.19 billion, Boylan remains optimistic about future growth prospects in this sector, citing J&J’s increased focus and investment in the area. Expectations are high for the upcoming launch of J&J’s Ottava surgical robot, which could rival Intuitive Surgical’s da Vinci system.

Overall, investors and analysts remain cautiously optimistic about Johnson & Johnson’s future prospects in the face of challenges posed by the volatile foreign exchange market and patent expirations. The company’s strategic focus on new products and technological advancements, coupled with strong performance in key areas, continues to drive investor confidence in the healthcare giant’s long-term growth potential.